FirstWord Pharma

Revolution Medicines’ pancreatic cancer drug has stunning commercial debut

Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs

Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic

This woman defied lethal cancer. Can mRNA vaccines make that possible for others?

Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail

Ferring Signs $1.4 Billion Deal to Buy Gameto Fertility Startup

Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO

Roche Targets Emerging Oncology Market With New Lung-Cancer Drug

AstraZeneca Readies New Portfolio of Targeted Cancer Therapies

As Politicians Argue About China, US Patients Find Cutting-Edge Treatment There

Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win

Roche returns to China’s Hansoh for $15B biobucks ADC pact

FDA approves once-daily Parkinson’s pill (Juvmo) built on decades of work by husband-and-wife team

Vir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEs

Verastem CEO claims RAS drug has 'set a new benchmark' for tricky cancer in early readout

FDA’s New Leadership Aims to Overhaul Rare Disease Approvals

BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence

BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth

US FDA approves Asahi Kasei's drug for persistent herpes infections

Exclusive: AI startup Chai lands GSK deal, its sixth pharma partner in nine months

Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down

Genentech pays Alector $100M for preclinical Parkinson’s prospect

Trump Administration Finalizes Plan to Lower Drug Prices in Medicare

Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study

Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial

Vera kidney drug Trutakna shows strong final results in Phase 3 trial

Psychedelics Stock, Up 190% This Year, Flies High Again

Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share

AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial

Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes

Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters

Novo Nordisk Says Wegovy Shot Helped Children Lose Weight in Trial

Novartis cholesterol setback tests hopes for emerging heart disease drugs

Early Data Indicates an A.I.-Generated Drug Could Slow Aging

Teva autoimmune antibody notches ph. 2 win in celiac disease

Novartis inks $3.2B subcutaneous delivery deal with Alteogen

Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody

GSK plans phase 3 after mRNA flu vaccine beats standard shots

Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials

Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused

Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism

A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass

AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review

Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal

A new ADHD drug targets three brain chemicals instead of two. Here’s what that means

Biotech Scores Again With LSD In Anxiety; Stock Rises

Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs

Regeneron backs $75M series A for antibody upstart Infinimmune

An Alzheimer’s Drug Cut Expected Cognitive Decline Roughly in Half. It Didn’t Target Amyloid

Silence Therapeutics aims at Takeda with new data in rare blood cancer

MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial

Study reveals new role for tau, a top target for Alzheimer’s drug development

‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E

Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments

Amgen drops ph. 1 obesity drug, upping pressure on MariTide

Eli Lilly to allow more patients to apply for special access to unapproved obesity drug

AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up

Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline

5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

FDA Panel Votes In Favor of Replimune’s Melanoma Treatment

9 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Argenx to Buy Forte Biosciences for $2.2 Billion

8 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.